Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Bio-Techne Corporation

A Tale of Two Biotech Giants: Gilead Sciences vs. Bio-Techne

In the ever-evolving landscape of biotechnology, understanding the financial dynamics of industry leaders is crucial. Over the past decade, Gilead Sciences, Inc. and Bio-Techne Corporation have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Gilead's SG&A costs surged by over 100%, peaking at approximately $6.09 billion in 2023. This reflects their aggressive expansion and strategic investments. In contrast, Bio-Techne's expenses grew by a staggering 550%, reaching nearly $397 million in 2024, indicating their rapid scaling and market penetration. Notably, Gilead's data for 2024 remains unavailable, leaving room for speculation on their future financial strategies. This comparison not only highlights the distinct growth trajectories of these biotech titans but also underscores the broader financial strategies shaping the industry. Dive deeper into these insights to understand the financial pulse of biotechnology.